Formin’ more conclusions.

We still don’t really know how to explain the noted improvement in cancer outcomes when metformin is used concurrent to radiation—maybe something to do with ameliorating the carcinogenic effects of hyperinsulinemia and/or hyperglycemia?—but that doesn’t keep this systematic review from investigating its use for pelvic malignancies. It concludes there is evidence of metformin increasing cell death for prostate, rectal and cervical cancers, particularly when p53 mutations are involved. | Clifford, Eur J Surg Oncol 2020